SAN DIEGO--(BUSINESS WIRE)--RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.
